Peptides DB
Research-centric peptide and protocol reference hub

Elamipretide record · updated 6h ago

Metabolic & appetiteHealing & recoveryGrade A · human clinicalResearch use only
All 9 studiesJump to the evidenceCompare
What is Elamipretide used for?

Research peptide discovered via AI researcher. peptide-based therapeutic

How it works: Stabilizes cardiolipin

Primarily researched for · Metabolic & appetite

Development stage

where Elamipretide sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 119 registered trials. It describes the research record, not a recommendation.

Identity
NameElamipretide
Chain length—
Molecular weight639.8 Da
FormulaC32H49N9O5
Structure typeNot established
ClassMetabolic
Research levelPreclinical
Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 11764719. No verified residue count for this compound.

Pharmacology
MechanismStabilizes cardiolipin
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence0.70
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 5, 2026. How this works →
Research stats
Total studies9
Human / animal / cellular3 / 1 / 0
Highest trial phasePreclinical
Years covered2026
Latest study17d ago
Publication history
20262026
Research funding
36 NIH projects · $15.7M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

9 rowsOpen in the library →
StudyTypeYearSummary depth
Advances and perspectives of functional nanomaterials in scavenging reactive oxygen species for acute kidney injury.
TakeawayNanomaterials offer potential for improved acute kidney injury therapies, but translational challenges remain significant.
review2026Full text read0.80
Knowledge gaps for neuromorphic ionic computing.
TakeawayNot reported in abstract.
—2026Title only0.10
Artificial platelets suppressing deep vein thrombosis via competitive adhesion.
Finding30% reduction in thrombosis in mouse DVT model (p<0.001).
Animal2026Full text read0.80
Influence of cigarette smoking on cardio-inflammatory biomarkers among healthy individuals or cardiopulmonary disorder patients: systematic review and meta-analysis.
FindingNot reported in abstract.
review2026Full text read0.80
Lipoprotein metabolism and inflammation in healthy young subjects - exploring the postprandial and postabsorptive phases following intake of a standardized meal.
Finding325% increase in IL-6 10 h after breakfast.
Human2026Full text read0.80
Psychometric properties of the Arabic translation of the PTGI-SF 10-item scale in adolescents.
Findingω = 0.73/α = 0.73
Human2026Full text read0.90
Clinical significance of soluble E-selectin and soluble vascular cell adhesion molecule-1 levels in umbilical cord blood for neonatal respiratory distress syndrome: a retrospective study.
FindingAUC for combined sE-selectin and sVCAM-1: 0.935.
Human2026Full text read0.80
Is an emerging pharmacotherapeutic era for rare mitochondrial diseases here?
TakeawayNot reported in abstract.
—2026Title only0.10
Early-stage type 1 diabetes: is there a role for lifestyle modifications?
TakeawayNot reported in abstract.
—2026Title only0.00

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Elamipretide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Elamipretide is discussed should be drawn from it.